前列回春胶囊联合特拉唑嗪治疗Ⅲb型慢性前列腺炎的临床研究
|
摘要
目的探讨前列回春胶囊联合特拉唑嗪治疗Ⅲb型慢性前列腺炎患者的临床疗效。方法选取城口县人民医院2015年1月—2018年6月收治的Ⅲb型慢性前列腺炎患者214例,每组各107例。对照组患者口服盐酸特拉唑嗪片,2.0 mg/次,1次/晚;治疗组患者在对照组的基础上口服前列回春胶囊,5粒/次,3次/d,两组患者均连续治疗3个月。观察两组患者临床疗效,同时比较治疗前后两组患者美国国立卫生研究院慢性前列腺炎症状指数(NIH-CPSI)和前列腺液(EPS)中相关细胞因子的情况。结果治疗后,对照组和治疗组临床有效率分别为74.8%和87.9%,两组比较差异具有统计学意义(P<0.05)。治疗后,两组的疼痛评分(PS)、排尿症状评分(USS)、生活质量评分(QLS)和NIH-CPSI评分均显著降低,同组治疗前后比较差异具有统计学意义(P<0.05);且治疗后治疗组PS、USS、QLS及NIH-CPSI评分均明显低于对照组,两组比较差异均有统计学意义(P<0.05)。治疗后,两组EPS中的肿瘤坏死因子-α(TNF-α)、增殖细胞核抗原(PCNA)、血管内皮生长因子(VEGF)和前列腺素2(PGE2)水平较治疗前均显著降低,EPS中白介素-2(IL-2)水平较治疗前升高,且治疗后治疗组EPS中相关细胞因子水平明显优于对照组,两组比较差异均有统计学意义(P<0.05)。结论前列回春胶囊联合特拉唑嗪治疗Ⅲb型慢性前列腺炎疗效显著,可以改善患者疼痛及排尿症状,提高生活质量,具有一定的临床推广应用价值。
Abstact: Objective To explore the clinical efficacy of Qianlie Huichun Capsules combined with terazosin in treatment of type Ⅲb chronic prostatitis. Methods Patients(214 cases) with type Ⅲb chronic prostatitis in Chengkou People's Hospital were randomly divided into control and treatment groups, and each group had 107 cases. Patients in the control group were po administered with Terazosin Hydrochloride Tablets, 2.0 mg/time, once every night. Patients in the treatment group were po administered with Qianlie Huichun Capsules 5 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, NIH-CPSI score and expressed prostatic secretions(EPS) related factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.8% and 87.9%, respectively, and there was difference between two groups(P < 0.05), and there were differences between two groups(P < 0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, TNF-α, PCNA, VEGF, and PGE2 levels in two groups were significantly decreased, but IL-2 level were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And those EPS related factors in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Qianlie Huichun Capsules combined with terazosin has clinical curative effect in treatment of type Ⅲb chronic prostatitis, and can improve pain, urination symptoms, and life quality, which has a certain clinical application value.
Abstact: Objective To explore the clinical efficacy of Qianlie Huichun Capsules combined with terazosin in treatment of type Ⅲb chronic prostatitis. Methods Patients(214 cases) with type Ⅲb chronic prostatitis in Chengkou People's Hospital were randomly divided into control and treatment groups, and each group had 107 cases. Patients in the control group were po administered with Terazosin Hydrochloride Tablets, 2.0 mg/time, once every night. Patients in the treatment group were po administered with Qianlie Huichun Capsules 5 grains/time, three times daily. Patients in two groups were treated for 3 months. After treatment, the clinical efficacy was evaluated, NIH-CPSI score and expressed prostatic secretions(EPS) related factors in two groups before and after treatment were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 74.8% and 87.9%, respectively, and there was difference between two groups(P < 0.05), and there were differences between two groups(P < 0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in two groups were significantly decreased, and the difference was statistically significant in the same group(P < 0.05). After treatment, PS, USS, QLS, and NIH-CPSI scores in the treatment group were significantly lower than those in the control group, with significant difference between two groups(P < 0.05). After treatment, TNF-α, PCNA, VEGF, and PGE2 levels in two groups were significantly decreased, but IL-2 level were significantly increased, and the difference was statistically significant in the same group(P < 0.05). And those EPS related factors in the treatment group were significantly better than those in the control group, with significant difference between two groups(P < 0.05). Conclusion Qianlie Huichun Capsules combined with terazosin has clinical curative effect in treatment of type Ⅲb chronic prostatitis, and can improve pain, urination symptoms, and life quality, which has a certain clinical application value.
引文
[1]Nickel J C,Nyberg L M,Hennenfent M.Research guidelines for chronic prostatitis:consensus report from the First National Institutes of Health International Prostatitis Collaborative Network[J].Urology,1999,54(2):229-233.
[2]尹航,王晓峰,白文俊,等.特拉唑嗪在ⅢB型前列腺炎治疗中的应用[J].临床泌尿外科杂志,2005,20(3):19-22.
[3]邹伟,刘武江.前列回春胶囊治疗Ⅲ型慢性前列腺炎的疗效观察[J].中国医学创新,2012,9(18):145-146.
[4]中国中西医结合学会男科专业委员会.慢性前列腺炎中西医结合诊疗专家共识[J].中国中西医结合杂志,2015,35(8):933-940.
[5]吴少祯.常见疾病的诊断与疗效判断(标准)[M].北京:中国中医药出版社,2001:529.
[6]Litwin M S,McNaughton-Collins M,Fowler F J Jr,et al.The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure[J].J Urol,1999,162(2):369-375.
[7]Antolak S J,Antolak C M.Chronic pelvic pain:neurogenic or non-neurogenic warm detection threshold testing supports a diagnosis of pudendal neuropathy[J].Pain Physician,2018,21(2):E125-E135.
[8]段登志,欧阳虹,王寅,等.前列回春胶囊的药理作用和临床应用浅析[J].云南中医中药杂志,1995,16(1):5-7.
[9]吴国伟,张彦君.非细菌性前列腺炎患者前列腺液中炎性因子水平在分型中的价值[J].医学检验与临床,2017,28(6):45-46.
[10]何乐业,王勇,龙智.慢性前列腺炎患者EPS中IL-2、IL-10和TNF-α的表达的临床意义[J].中国男科学杂志,2009,23(2):38-41.
[11]李永伟,王春霞,何志强.前列腺液中PGE2水平与慢性非细菌性前列腺炎的相关性研究[J].现代预防医学,2012,39(20):5431-5432.
[12]胡广平,毕学成,何慧婵,等.PCNA在前列腺癌及良性前列腺增生症组织中的表达及其临床意义[J].岭南现代临床外科,2008,8(4):285-286.
[13]任海林,陈国俊,李晓娜,等.前列腺基质细胞在低氧条件下ROS、VEGF及IL-8的表达及其对细胞生长的影响[J].实用医学杂志,2015,31(9):1411-1413.
[14]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织PCNA表达的影响[J].中国医药学报,2003,18(9):565-566.
[15]段登志,张鸿青,于玲,等.前列回春对实验性大鼠前列腺组织血管内皮生长因子表达的影响[J].中华男科学,2004,10(2):152-154.
[2]尹航,王晓峰,白文俊,等.特拉唑嗪在ⅢB型前列腺炎治疗中的应用[J].临床泌尿外科杂志,2005,20(3):19-22.
[3]邹伟,刘武江.前列回春胶囊治疗Ⅲ型慢性前列腺炎的疗效观察[J].中国医学创新,2012,9(18):145-146.
[4]中国中西医结合学会男科专业委员会.慢性前列腺炎中西医结合诊疗专家共识[J].中国中西医结合杂志,2015,35(8):933-940.
[5]吴少祯.常见疾病的诊断与疗效判断(标准)[M].北京:中国中医药出版社,2001:529.
[6]Litwin M S,McNaughton-Collins M,Fowler F J Jr,et al.The National Institutes of Health chronic prostatitis symptom index:development and validation of a new outcome measure[J].J Urol,1999,162(2):369-375.
[7]Antolak S J,Antolak C M.Chronic pelvic pain:neurogenic or non-neurogenic warm detection threshold testing supports a diagnosis of pudendal neuropathy[J].Pain Physician,2018,21(2):E125-E135.
[8]段登志,欧阳虹,王寅,等.前列回春胶囊的药理作用和临床应用浅析[J].云南中医中药杂志,1995,16(1):5-7.
[9]吴国伟,张彦君.非细菌性前列腺炎患者前列腺液中炎性因子水平在分型中的价值[J].医学检验与临床,2017,28(6):45-46.
[10]何乐业,王勇,龙智.慢性前列腺炎患者EPS中IL-2、IL-10和TNF-α的表达的临床意义[J].中国男科学杂志,2009,23(2):38-41.
[11]李永伟,王春霞,何志强.前列腺液中PGE2水平与慢性非细菌性前列腺炎的相关性研究[J].现代预防医学,2012,39(20):5431-5432.
[12]胡广平,毕学成,何慧婵,等.PCNA在前列腺癌及良性前列腺增生症组织中的表达及其临床意义[J].岭南现代临床外科,2008,8(4):285-286.
[13]任海林,陈国俊,李晓娜,等.前列腺基质细胞在低氧条件下ROS、VEGF及IL-8的表达及其对细胞生长的影响[J].实用医学杂志,2015,31(9):1411-1413.
[14]段登志,于玲,张鸿青,等.前列回春对实验性大鼠前列腺组织PCNA表达的影响[J].中国医药学报,2003,18(9):565-566.
[15]段登志,张鸿青,于玲,等.前列回春对实验性大鼠前列腺组织血管内皮生长因子表达的影响[J].中华男科学,2004,10(2):152-154.